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Abstract
Somatic mutations in cervical intraepithelial neoplasia (CIN) are largely unknown. Here, we profiled 35 cervical
carcinomas and 23 CIN grade 2/3 (CIN2/3) for mutations in 48 cancer-related genes using a Next Generation
Sequencing-based cancer panel. PIK3CA exon 9 was the most frequently mutated locus in cervical carcinoma
and the only mutated locus detected in CIN2/3. These PIK3CA exon 9 mutation findings were verified in a
large, independent series (n5 647) covering all stages of cervical carcinogenesis using high resolution
melting-guided Sanger sequencing. PIK3CA exon 9 mutation frequency was 37.1% (13/35; 95%CI 21.2–
54.0%) in cervical carcinoma, and 2.4% (5/209; 95%CI 0.5–4.7%) in CIN3. No PIK3CA exon 9 mutations
were detected in CIN2 (0/144), CIN1 (0/154) and normal cervix (0/105). In a third series of 46 CIN2/3 lesions
from women with a known 5-year history of preceding high-risk human papillomavirus (hrHPV) infection,
detection of PIK3CA exon 9 mutation was confined to 2 (5.4%; 95%CI 0.0–13.2%) CIN3 lesions with preced-
ing hrHPV infection 5 years, and was absent in those with a short duration (<5 years) of preceding hrHPV
infection. In conclusion, somatic mutation in PIK3CA represents a late event during cervical carcinogenesis,
detected in a substantial subset of cervical carcinoma, but only in a minority of CIN3.
Keywords: cervix uteri; DNA sequencing; dysplasia
Received 18 June 2015; accepted 29 July 2015
Conflict of interest: P. Snijders, C. Meijer, R. Steenbergen and D. Heideman have minority stakes in Self-screen B.V., a spin-off company of VU Univer-
sity Medical Center. D. Heideman serves occasionally on the scientific advisory boards of Amgen and Pfizer. C. Meijer has been on the sponsored
speakers bureau of GlaxoSmithKline, Qiagen, Merck, Roche, Menarini and Seegene, and served occasionally on the scientific advisory board of GlaxoS-
mithKline, Qiagen, Merck, and Roche. C. Meijer has occasionally been consultant for Qiagen and Genticel and is a minority shareholder of Diassay B.V.
P. Snijders has been on the speakers bureau of Roche, Qiagen, Abbott, Gen-Probe and Seegene. P. Snijders is consultant for Crucell Holland B.V. All
other authors declare no conflicts of interest.
Introduction
A persistent infection with high-risk human papillo-
mavirus (hrHPV) is the necessary cause of cervical
cancer, yet additional genetic and epigenetic host cell
aberrations are required for progression to invasive
cancer [1]. To date, genomic studies on cervical can-
cer and its squamous precursor lesions, cervical intra-
epithelial neoplasia (CIN) grade 1-3, have mostly
focused on chromosomal aberrations and epigenetic
features [1,2]. A few studies, mainly restricted to cer-
vical cancer, have concentrated on somatic mutations.
These studies have revealed PIK3CA as the most fre-
quently mutated gene with frequencies of 5.7–35.7%
[3–11]. So far, CIN lesions have not been subjected
to mutation analysis in a comprehensive manner. It
therefore remains unclear at what stage during cervi-
cal carcinogenesis somatic mutations occur. In this
study, we perform comprehensive mutation profiling
of squamous precursor lesions of cervical cancer.
Materials and methods
Clinical specimens
Frozen tissue specimens of cervical squamous cell
carcinoma (SCC, n525), cervical adenocarcinoma
(AdCA, n5 10) and CIN2/3 (n5 23) were used for
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mutation profiling of 48 cancer-related genes using a
Next Generation Sequencing (NGS)-based cancer
panel (further referred to as TSACP-MiSeq-NGS).
Given limitations in accurate histological grading of
high-grade CIN on frozen tissue sections, CIN2 and
CIN3 were grouped together in the frozen tissue sam-
ple set. An independent series of formalin-fixed par-
affin-embedded (FFPE) tissue specimens covering all
stages of cervical carcinogenesis was used for verifi-
cation studies by high resolution melting-guided
Sanger sequencing. This series consisted of cervical
SCC (n5 28), cervical AdCA (n5 7), CIN3
(n5 209), CIN2 (n5 144), CIN1 (n5 154) and nor-
mal cervical epithelium (n5 105). An additional
FFPE series of CIN2 (n5 3) and CIN3 (n5 43) was
from women participating in the Population Based
Screening Study Amsterdam (POBASCAM) and
detected in the second screening round (interval 5
years) in the control arm (cytology screening with
blind HPV testing) [12]. Accordingly, the 5-year his-
tory of hrHPV infection of these women was known.
The duration of preceding hrHPV infection (PHI)
was considered as a proxy for duration of lesion exis-
tence [13]. Women with the same hrHPV-type in
their biopsy compared to baseline have PHI 5 years
and were considered to have more advanced lesions
(n5 3 CIN2; n5 34 CIN3). Women who acquired
the hrHPV infection after study entrance (PHI< 5
years) were considered to have early lesions (n5 9
CIN3). The study followed the ethical guidelines of
VU University Medical Center.
TSACP-MiSeq-NGS and PIK3CA exon 9 HRM-
sequencing
Genomic DNA was isolated by Qiagen DNA Micro
kit (Qiagen, Hilden, Germany) or easyMAG (Bio-
merieux, Marcy I’Etoile, France) according to the
manufacturer’s instructions. Genomic DNA from fro-
zen tissue specimens was subjected to amplicon-
based NGS using TruSeq Amplicon Cancer Panel
(TSACP; Illumina, San Diego, CA, USA) and the
MiSeq Personal Sequencer (Illumina), essentially as
described before [14]. TSACP covers 212 amplicons
from 48 cancer-related genes, which are simultane-
ously amplified in a single-tube reaction. A minimal
variant allele frequency (VAF) of 0.05 was used to
score mutations. High-resolution melting followed by
Sanger sequencing (HRM-sequencing) for PIK3CA
exon 9 was applied to genomic DNA from FFPE-
tissue specimens, as previously described [14].
Statistical analysis
Mutation frequencies were calculated with 95% con-
fidence intervals (CI). Differences between groups
were analysed by Chi-square test using cross-
tabulation. A p-value below 0.05 was considered stat-
istically significant. Statistical analysis was per-
formed with IBM SPSS v20.
Results
Mutation profiling of cervical carcinoma and
CIN2/3
To evaluate the presence of somatic hotspot muta-
tions in 48 cancer-related genes, a NGS-based panel
(TSACP-MiSeq-NGS) was applied to 25 SCC, 10
AdCA and 23 CIN2/3 (Table 1). Sixteen tumours
(45.7%; 95%CI 28.6–62.9%) showed one or more
non-synonymous mutations. Overall mutation fre-
quency was comparable between SCC (12/25; 48.0%;
95%CI 27.6–68.0%) and AdCA (4/10; 40.0%; 95%CI
11.1–71.4%; p5 0.668). Most tumours harboured a
single mutation (13/16; 81.3%). Co-occurrence of
mutations was found in three tumours: PIK3CA and
FBXW7 (n5 1 SCC), PIK3CA and TP53 (n5 1
SCC), and PTEN and ATM (n5 1 AdCA). PIK3CA
exon 9 was the most frequently mutated locus in cer-
vical carcinoma (overall: 7/35; 20.0%; 95%CI 8.0–
34.1%; SCC: 6/25; 24.0%; 95%CI 8.3–43.8% and
AdCA: 1/10; 10.0%; 95%CI 0.0–33.3%) with median
VAF of 0.23 (range 0.09–0.63). All PIK3CA muta-
tions involved hotspot sites in exon 9, ie, codon 542
(2/7; 28.6%) and codon 545 (5/7; 71.4%). Only one
CIN2/3 (4.3%; 95%CI 0.0–14.3%) harboured a muta-
tion, concerning PIK3CA p.E542K (VAF of 0.05).
PIK3CA exon 9 mutations in an independent set
covering all stages of cervical carcinogenesis
Given that PIK3CA exon 9 was the most frequently
mutated locus, further mutation scanning was per-
formed by HRM-sequencing spanning that locus.
Testing of the above series by HRM-sequencing veri-
fied the TSACP-MiSeq-NGS results for PIK3CA
exon 9. Next, a large independent series comprising
28 SCC, 7 AdCA, 209 CIN3, 144 CIN2, 154 CIN1
and 105 normal cervical epithelium, was evaluated to
investigate the onset of PIK3CA exon 9 mutations
during cervical cancer development (Table 2A).
PIK3CA exon 9 mutations were detected in 13 cervi-
cal cancers (37.1%; 95%CI 21.2–54.0%), including
12 SCC (42.9%; 95%CI 23.8–62.5%) and 1 AdCA
(14.3%; 95%CI 0.0–50.0%). Mutation frequency
tended to be higher in SCC, but the difference
between the two histological types was not signifi-
cant (p5 0.162). Most mutations involved hotspots at
codon 542 (6/13; 46.0%) or 545 (6/13; 46.0%). Five
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CIN3 lesions (2.4%; 95%CI 0.5–4.7%) showed a
PIK3CA exon 9 hotspot mutation, ie, p.E542K (1/5;
20.0%) and p.E545K (4/5; 80.0%). PIK3CA exon 9
mutations were not found in CIN2, CIN1 and normal
cervical epithelium.
PIK3CA exon 9 mutations in CIN2 and CIN3 with
different durations of lesion existence
Finally, we assessed the occurrence of PIK3CA exon
9 mutations in relation to duration of lesion exis-
tence. To this end, we analysed an independent series
of CIN2 and CIN3 diagnosed in women participating
in the POBASCAM trial with a known 5-year history
of preceding hrHPV infection [13]. These comprised
early (n5 9) lesions from women with a known pre-
ceding hrHPV infection of <5 years, and advanced
(n5 37) lesions from women with a preceding
hrHPV infection lasting 5 years as a proxy of lon-
ger duration of lesion existence. Two advanced CIN3
lesions (5.4%; 95%CI 0.0–13.2%) harboured a
PIK3CA (p.E545K) mutation, but none of the early
lesions (Table 2B).
Discussion
This study shows that somatic mutations in PIK3CA
represent a late event during cervical carcinogenesis.
A substantial subset of cervical carcinomas harboured
a PIK3CA exon 9 mutation, but only a minority of
CIN3, and no CIN2 or CIN1. The low VAF of
PIK3CA exon 9 mutation in cervical cancer suggests
that it is present in subclones and further supports
this being a late event in tumour evolution. In a lim-
ited number of high-grade CIN with known duration
Table 1. Mutations in cervical carcinoma and CIN2/3 as assessed by TSACP-MiSeq-NGS
Mutation
CIN2/3
(n5 23)
n (VAF)
SCC
(n5 25)
n (VAF)
AdCA
(n5 10)
n (VAF)Gene
CDS
change
Amino acid
change
PIK3CA c.1624G>A p.E542K 1 (0.05) 2 (0.13, 0.61) 0
c.1633G>A p.E545K 0 4 (0.091, 0.14, 0.23, 0.322) 0
c.1633G>C p.E545Q 0 0 1 (0.63)
FBXW7 c.1273C>G p.R425G 0 2 (0.141, 0.16) 0
PTEN c.65A>G p.D22G 0 1 (0.39) 0
c.724G>T p.E242* 0 0 1 (0.713)
APC c.3400G>C p.D1134H 0 1 (0.30) 0
STK11 c.597G>C p.E199D 0 1 (0.23) 0
AKT1 c.82C>G p.L28V 0 1 (0.11) 0
RB1 IVS3-1G>C Acceptor splice site 0 1 (0.57) 0
TP53 c.586C>T p.R196* 0 1 (0.062) 0
NRAS c.182A>G p.Q61R 0 0 1 (0.30)
GNA11 c.972C>G p.I324M 0 0 1 (0.15)
ATM c.7322T>G p.V2441G 0 0 1 (0.503)
AdCA, adenocarcinoma; CDS, coding DNA sequence; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; TSACP-MiSeq-NGS, TruSeq Amplicon
Cancer Panel-based Next Generation Sequencing on the MiSeq Personal Sequencer; VAF, variant allele frequency depicted for each mutated specimen
separately.
1,2,3 Co-occurrence of mutations (number indicating the combination).
Table 2. Overview of PIK3CA exon 9 mutations in cervical tissue specimens as assessed by HRM-sequencing
A. Cross-sectional series stratified by histological grade
B. CIN2 and CIN3
stratified by known
duration of preceding
hrHPV infection
PIK3CA exon 9 mutation
Normal
(n5 105)
n (%)
CIN1
(n5 154)
n (%)
CIN2
(n5 144)
n (%)
CIN3
(n5 209)
n (%)
SCC
(n5 28)
n (%)
AdCA
(n5 7)
n (%)
Early
(n59)
n (%)
Advanced
(n5 37)
n (%)CDS change
Amino acid
change
c.1624G>A p.E542K 0 (0) 0 (0) 0 (0) 1 (0.5) 5 (17.9) 0 (0) 0 (0) 0 (0)
c.1624G>C p.E542Q 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 0 (0) 0 (0) 0 (0)
c.1633G>A p.E545K 0 (0) 0 (0) 0 (0) 4 (1.9) 5 (17.9) 1 (14.3) 0 (0) 2 (5.4)
c.1637A>G p.Q546R 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 0 (0) 0 (0) 0 (0)
Overall 0 (0) 0 (0) 0 (0) 5 (2.4) 12 (42.9) 1 (14.3) 0 (0) 2 (5.4)
AdCA, adenocarcinoma; Advanced, CIN2 (n5 3) and CIN3 (n5 34) from women with a preceding hrHPV infection 5 years; CDS, coding DNA sequence; CIN,
cervical intraepithelial neoplasia; Early, CIN3 from women with a preceding hrHPV infection <5 years; SCC, squamous cell carcinoma.
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of preceding hrHPV infection, PIK3CA mutations
were only present in so-called advanced CIN3, and at
low prevalence. By combining the current findings
with those from our previous studies, we may infer
the timing of different (epi)genetic aberrations fol-
lowing the initiating event (ie, a transforming hrHPV
infection) during cervical carcinogenesis. Relative to
chromosomal aberrations and altered DNA methyla-
tion, which are detectable in the great majority of
cervical carcinomas and advanced CIN3 [1,13,15,16],
PIK3CA mutations can be considered a late event.
To the best of our knowledge, this is the first study
evaluating large series of CIN for somatic mutations.
Mutations in cancer-related genes were present in
almost half of cervical carcinomas. The finding that
PIK3CA is the most frequently mutated gene in cer-
vical cancers is in line with previous reports [3–11].
However, mutations in cancer-related genes appeared
to be rare in CIN lesions. To date, no PIK3CA muta-
tions have been reported in CIN, but earlier studies
comprised limited sample series [5,8].
A limitation of our study might be seen in the tar-
geted NGS approach. Mutations outside the targeted
genomic regions thereby remain undetected, with
potential underrepresentation of overall mutation fre-
quency as a result. Furthermore, the technology may
be restricted in the identification of subclonal muta-
tions that might be present at a VAF below the
detection threshold of the assay. In addition, no nor-
mal DNA was available to verify the somatic origin
of the mutations identified.
Of the PIK3CA mutations found, the only mutated
locus in this gene was exon 9. In fact, the majority
of these PIK3CA mutations (25/28; 89.3%) were hot-
spot mutations p.E542K (c.1624G>A) and p.E545K
(c.1633G>A). These alterations both correspond to
C>T (ie, G>A on the opposing strand) mutations at
a TCW (W5A or T) trinucleotide motif. Previously,
a significant skew towards TCW mutations in
PIK3CA was found in hrHPV-positive head and neck
SCC, suggesting involvement of apolipoprotein B
mRNA editing enzyme (APOBEC) [17]. These
enzymes are normally involved in deamination of
cytosines, which results in conversion to uracil, dur-
ing RNA editing. Replacement of uracil in the DNA
generally results in mutations to thymine or guanine
[17,18]. A role for APOBEC in response to hrHPV
infection has been proposed as a host defence mecha-
nism and is hypothesized to trigger APOBEC-
signature mutations in hrHPV-associated cancers
[19].
Apart from mutations at hotspot codons 542 and
545, p.Q546R was present in one cervical carcinoma.
The latter has not previously been described in cervi-
cal cancer, but has been reported in other cancer
types, such as colon cancer [20]. Mutations in other
genes were rarely identified in cervical carcinoma.
The second most mutated gene in SCC was FBXW7,
with a frequency (8.0%; 95%CI 0.0–20.0%) in-
between previously published rates (1.5–15.0%), but
these concerned other base substitutions [4,7].
In conclusion, PIK3CA exon 9 mutations occur in
a substantial subset of cervical cancer, while rarely in
CIN3, and not in lower grade CIN nor normal cervix.
Our data support that PIK3CA mutations represent a
late event during cervical carcinogenesis.
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